

**GEORGIA BIO™ PRESENTS THE**  
**GEORGIA LIFE SCIENCES SUMMIT 2008**

*Molecules, Materials & Minds ~ Building Georgia's INNOVATION Economy*

**CONFERENCE PROGRAM**

<b>8:00 AM</b>	<b>OPENING REMARKS</b> Thomas H. Callaway, MD; <i>President, Life Science Partner and Managing Director, Georgia Venture Partners</i>  <b>WELCOME</b> The Honorable Shirley Franklin; <i>Mayor, City of Atlanta</i>
<b>8:10 AM</b>	<b>INTRODUCTION OF JAMES C. GREENWOOD</b> Phillip Street; <i>Kilpatrick Stockton LLP</i>  <b>BIOTECH INNOVATION: HEALING, FUELING &amp; FEEDING THE WORLD</b> James C. Greenwood; <i>President and Chief Executive Officer, Biotechnology Industry Organization</i>
<b>8:30 AM</b>	<b>INTRODUCTION OF TANJA POPOVIC</b> Alexis V. Pezzullo; <i>KPMG LLP</i>  <b>THE MAKING OF A HEALTHIEST NATION: NOT IF. NOT WHEN. NOW!</b> Tanja Popovic, MD, PhD; <i>Chief Science Officer, U.S. Centers for Disease Control and Prevention</i>
<b>9:00 AM</b>	<b>INTRODUCTION OF STEPHEN A. HILL</b> Walt Linscott; <i>Thompson Hine LLP</i>  <b>BIOPHARMACEUTICALS: BACK TO THE FUTURE</b> Stephen A. Hill, BM, BCh, MA, FRCS; <i>President and Chief Executive Officer, Solvay Pharmaceuticals</i>
<b>9:30 AM</b>	<b>INTRODUCTION OF THE HONORABLE LOUIS W. SULLIVAN</b> Tina McKeon; <i>Fish and Richardson P.C.</i>  <b>NATIONAL HEALTH MUSEUM: THE GLOBAL CENTER FOR HEALTH AND WELLNESS</b> The Honorable Louis W. Sullivan, MD; <i>President Emeritus, Morehouse School of Medicine</i>
<b>9:50 AM</b>	<b>INTRODUCTION OF DIAGNANO</b> Robert T. McNally, PhD; <i>President and Chief Executive Officer, GeoVax</i>  <b>DIAGNANO: A NANOTECHNOLOGY OPPORTUNITY IN THE DIAGNOSTIC MARKETPLACE</b>
<b>10:00 AM</b>	<b>INTRODUCTION OF THE EXHIBIT, POSTER VIEWING AND MORNING CONCURRENT FOCUS SESSIONS</b> William Kitchens; <i>Arnall Golden Gregory LLP</i>  <b>REFRESHMENTS</b>
<b>10:30 AM</b>	<b>MORNING CONCURRENT FOCUS SESSIONS</b> 1a. <i>Forces Shaping the Emerging Bioeconomy in Agriculture</i> 1b. <i>Traversing the Regulatory and Clinical Compliance Maze: From Preclinical to Market Approval</i> 1c. <i>The Next Generation of Georgia's Life Science Companies</i> 1d. <i>Cardiovascular Innovation in Public-Private Partnerships</i>
<b>11:45 AM</b>	<b>LUNCH</b>
<b>12:45 PM</b>	<b>INTRODUCTION OF RESEARCH ADVANCES IN GEORGIA</b> Jack Capers; <i>King and Spalding</i>  <b>RESEARCH ADVANCES IN GEORGIA: NEUROSCIENCE</b> <i>SPONSORED BY SOLVAY PHARMACEUTICALS, INC.</i>
<b>2:10 PM</b>	<b>INTRODUCTION OF CARTIMESH</b> Robert T. McNally, PhD; <i>President and Chief Executive Officer, GeoVax</i>  <b>CARTIMESH: A LIVING IMPLANT FOR HEALING KNEE CARTILAGE</b>
<b>2:20 PM</b>	<b>EXHIBIT AND POSTER VIEWING / REFRESHMENTS</b>
<b>2:50 PM</b>	<b>AFTERNOON CONCURRENT FOCUS SESSIONS</b> 2a. <i>Medical Devices in Georgia - presented in partnership with the Southeast Medical Device Association</i> 2b. <i>"Delivering the Golden Egg" - IPOs, M&amp;A and Partnering in the Life Sciences Industry</i> 2c. <i>Bioenergy: A Fuel for Success</i> 2d. <i>Why Georgia?: The Ascent and Maturation of Georgia's Talent Pool and Biotech Labor Market presented by The GaBio Emerging Leaders Network</i>

## CONFERENCE PROGRAM CONTINUED...

<b>4:20 PM</b>	<b>INTRODUCTION OF GOVERNOR SONNY PERDUE</b> <i>Michelle Williams; Alston and Bird LLP</i>  <b>KEYNOTE ADDRESS</b> <i>The Honorable Sonny Perdue, DVM; Governor, State of Georgia</i>  <b>GEORGIA BIO HONORS SENATOR BOB DOLE FOR HIS CONTRIBUTION TO UNIVERSITY-BASED INNOVATION</b> <i>Senator Bob Dole; Special Counsel, Alston and Bird LLP</i>  <b>28 YEARS OF IMPACT: THE BAYH-DOLE ACT ACCELERATED THE REALIZATION OF GEORGIA'S BIOTECHNOLOGY ECONOMY</b> <i>C. Michael Cassidy - Moderator; President and Chief Executive Officer, Georgia Research Alliance</i> <i>Michael F. Adams, PhD; President, The University of Georgia</i> <i>James W. Wagner, PhD; President, Emory University</i>  <b>CONCLUDING REMARKS</b> <i>Senator Bob Dole; Special Counsel, Alston and Bird LLP</i>
<b>5:50 PM</b>	<b>ANNOUNCEMENT OF POSTER WINNERS</b> <i>Anthony J. Shuker, PhD - Moderator</i> <i>David Wynes, PhD - Moderator; Vice President for Research Administration, Emory University</i>  <b>PRESENTATION OF AWARDS</b> <i>Stephen Bell, PhD, MBA; Senior Vice President, Saint Joseph's Translational Research Institute</i>
<b>6:05 PM</b>	<b>CLOSING REMARKS</b> <i>Thomas H. Callaway, MD; President, Life Science Partner and Managing Director, Georgia Venture Partners</i>
<b>6:15 PM</b>	<b>GALA PARTY</b> Casino Night at the Georgia World Congress Center

## **DIAGNANO: A NANOTECHNOLOGY OPPORTUNITY IN THE DIAGNOSTIC MARKETPLACE (9:50 AM - 10:00 AM)**

DiagNano is an early stage technology venture focusing on *in vitro* diagnostics. We will offer nanotechnology-based products for tissue biopsy analysis to provide clinicians with a patient-specific cancer fingerprint. We are currently applying for grants (GRA VentureLab and SBIR) to continue research and development and begin clinical testing.

**Kristina Crockett, MBA;** *Project Manager, McKesson – RelayHealth*

**Laura Huffman, JD;** *IP Associate, King and Spalding*

**Brad Kairdolf;** *PhD candidate in Biomedical Engineering, Georgia Tech and Emory*

---

## **MORNING CONCURRENT FOCUS SESSIONS (10:30 AM – 11:45 AM)**

### **1a. FORCES SHAPING THE EMERGING BIOECONOMY IN AGRICULTURE**

Global agriculture is at a defining moment. Society looks to policy makers and leadership groups in agriculture to develop solutions for world hunger, biofuels, drought and management of water resources, zoonotic and pandemic diseases, scarce land resources and a safe food supply. Agriculture is in a key position to provide these solutions as long as technology is adopted and optimally used. During this session, you will hear some of the leaders in Agribusiness speak on how they are positioning their organizations for winning solutions and strategies to meet these challenges.

**Clifton A. Baile, PhD - Moderator;** *Georgia Research Alliance Eminent Scholar in Agricultural Biotechnology and Distinguished Professor of Animal Science and Foods and Nutrition, The University of Georgia*

**Gregg W. BeVier, DVM, MBA - Moderator;** *Chief Executive officer, AgGlobalVision*

**Dennis T. Avery;** *Senior Fellow of the Hudson Institute and Director of its Center for Global Food Issues*

**Don W. Mabe Jr.;** *Senior Vice President Regional Operations, Case Ready Division, Pilgrim's Pride Corporation*

**William H. Sperber, PhD;** *Global Ambassador for Food Protection, Cargill, Inc.*

---

### **1b. TRAVERSING THE REGULATORY AND CLINICAL COMPLIANCE MAZE: FROM PRECLINICAL TO MARKET APPROVAL**

The focus of this breakout session is to address 1) Working/Communicating Effectively with FDA; 2) Overview of Regulatory Submissions; and 3) Clinical Trials--Common Pitfalls & Challenges.

**David W. Mullis, Jr., PhD, RAC – Moderator;** *President, Mullis and Associates*

**Stephanie E. Hubbard;** *Bioresearch Monitoring Specialist, Food and Drug Administration*

**Alan G. Minsk;** *Partner and Chair of the Food and Drug Practice Team, Arnall Golden Gregory LLP*

**Mamta Trivedi;** *Global Senior Director, QLAB, Global Quality Assurance, Central Labs, Quintiles Transnational Corp.*

---

### **1c. THE NEXT GENERATION OF GEORGIA'S LIFE SCIENCE COMPANIES**

Georgia is home to some of the leading young companies in the life science industry. This session will feature presentations by some of our most innovative emerging companies. This group of companies provides a window into the future of the life science industry in Georgia and the Southeast.

**H. Lee Herron, DVM - Moderator;** *Vice President of Commercialization, Georgia Research Alliance*

**Kurt Jacobus, PhD;** *Chief Executive Officer and President, MedShape Solutions, Inc.*

**David Johnston, PhD;** *Chief Executive Officer, AerovectRx Corporation*

**Jack Merritt;** *President and Chief Executive Officer, ICON Interventional Systems, Inc.*

## **1d. CARDIOVASCULAR INNOVATION IN PUBLIC-PRIVATE PARTNERSHIPS**

Cardiovascular disease remains the nation's number one health care problem and Georgia has some of the highest rates in the country for heart disease, stroke and hypertension. There is a need not only for new technologies for cardiovascular disease but also for new delivery and business models that can function in the rapidly changing and increasingly challenging regulatory and reimbursement environment. Atlanta doctors, institutions, and universities have been at the forefront of both technological and programmatic solutions. This panel will bring together some of these key innovators in cardiology and cardiac surgery as well as administrators from the region's leading cardiovascular institutions to discuss these challenges. Issues and challenges surrounding the use of public/private partnerships to bring new products to market will also be addressed.

**Jay S. Yadav, MD - Moderator;** *Chairman and Chief Executive Officer, CardioMEMS*

**Todd T. Sherer, PhD - Moderator;** *Associate Vice President for Research and Director, Office of Technology Transfer, Emory University*

**Nic Chronos, MD;** *President, St. Joseph's Translational Research Institute*

**Omar M. Lattouf, MD, PhD, FACS, FACC;** *Associate Professor of Surgery / Cardiothoracic, Emory University, Inventor, Founder and Principal of TransCardiac Therapeutics, Inc.*

**Michele M. Molden, FACHE;** *President and Chief Executive Officer, Piedmont Heart Institute*

**David L. West, PhD, MPH;** *Vice President, Medical Device Development, Quintiles Consulting*

---

## **RESEARCH ADVANCES IN GEORGIA: NEUROSCIENCE (12:45 PM – 2:10 PM)**

Neuroscience is one of the strongest areas of interdisciplinary and inter-institutional research in Georgia. This research is pushing the envelope on one of science's last and most daunting frontiers — the brain. This work holds great promise for understanding basic brain function and treating illnesses such as Alzheimer's disease and post traumatic stress disorder. The Center for Behavioral Neuroscience will host this plenary session where speakers will discuss recent advances in neuroscience research from the laboratories of scientists at Georgia's research universities.

**H. Elliott Albers, PhD - Moderator;** *Regents Professor, Georgia State University, Director, Center for Behavioral Neuroscience*

**Dennis W. Choi, MD, PhD;** *Executive Director, Comprehensive Neurosciences Initiative, Professor of Neurology, Biology, and Pharmacology, Emory University*

**Stephen P. DeWeerth, PhD;** *Professor and Associate Chair for Graduate Studies, Wallace H. Coulter Department of Biomedical Engineering, Georgia Tech/Emory University*

**Gaylen L. Edwards, DVM, PhD;** *Professor and Department Head, Department of Physiology and Pharmacology, College of Veterinary Medicine, The University of Georgia*

**Peter R. MacLeish, PhD;** *Director, Neuroscience Institute, Morehouse School of Medicine*

**Walt Wilczynski, PhD;** *Professor of Psychology, Director, Neuroscience Institute, Center for Behavioral Neuroscience, Georgia State University*

**Robert K. Yu, PhD, MedScD;** *Professor and Director, Institute of Molecular Medicine and Genetics, Medical College of Georgia*

---

## **CARTIMESH: A LIVING IMPLANT FOR HEALING KNEE CARTILAGE (2:10 PM – 2:20 PM)**

Articular cartilage is the tissue lining the ends of long bones, and it provides the friction-free bearing surface in joints such as the knee, shoulder, and hip. Repetitive use of the joints over the years irritates and inflames the cartilage, causing the tissue to degenerate and leads to osteoarthritis. Damage to this tissue through either sports-related or impact injuries also eventually leads to osteoarthritis since it has very little capacity for regeneration. This results in severe pain and loss of mobility and quality of life. Current clinical treatments range from simple surgical interventions (*e.g.* microfracture) to autologous tissue implantation (*e.g.* osteochondral grafts). However these therapies usually lead to sub-optimal results.

For this purpose, we have created a living cartilage implant using cartilage cells and biodegradable polymeric scaffolds. Cells from the articular cartilage are isolated, expanded, and cultured on a nanofiber scaffold to create a dual layered cartilage construct that can be implanted into the defect in the patient's cartilage. With time, this cartilage implant will be integrated with the host tissue, returning the joint to a normal state, and thus enabling patients to again maintain an active lifestyle.

**Yash Kolambkar;** *Georgia Institute of Technology*

**Ivan Mihailov;** *Emory University*

**Anil Patel;** *Emory University*

Jordan Scott; *Georgia Institute of Technology*

## **AFTERNOON CONCURRENT FOCUS SESSIONS (2:50 PM – 4:20 PM)**

**2a. MEDICAL DEVICES IN GEORGIA** *PRESENTED IN PARTNERSHIP WITH THE SOUTHEAST MEDICAL DEVICE ASSOCIATION*

**John G. Edwards - Moderator;** *Chief Executive Officer, Apeliotus Technologies*

### **Why Medical Devices are Hot**

This segment will explore some of the reasons that medical devices are strong in today's market, including attractive investment/return dynamics, strong options for exits, and recent Supreme Court decisions (*Riegel v. Medtronic*, *Warner-Lambert v. Kent*) that shield FDA approved medical devices from liability claims at the state level.

**Keith A. Barritt;** *Principal, Fish & Richardson P.C.*

**Ted Davis;** *Vice President, Business Development, Wright Medical Group*

**Al Lauritano;** *Director, Business Development, BD Technologies*

### **Georgia Makes its Mark in Medical Devices**

This segment will present three Georgia medical device company success stories.

**Mark J. Phelps, PhD;** *Senior Vice President of Research and Development, LIFESYNC Incorporated*

**Robert Scott, PhD;** *Director, Polymer Research, CIBA Vision Corporation*

**Brian Walsh;** *President, Dornier MedTech America*

---

## **2b. "DELIVERING THE GOLDEN EGG" - IPOs, M&A AND PARTNERING IN THE LIFE SCIENCES INDUSTRY**

Investors put money into emerging life science companies expecting to profitably take money out later. This "exit" ordinarily takes the form of either going public or being acquired by a larger company. What is the current status of IPOs and M&A in the industry? And how does partnering affect the eventual exit for a company? Our panel of industry experts will provide up-to-date insights.

**Howard D. Palefsky - Moderator;** *General Partner/Managing Member, Montreux Equity Partners*

**Steven P. Damon;** *Vice President, Business Development, Altea Therapeutics*

**Randy Guggenheimer;** *Managing Director, Burrill & Company*

**Bruce C. Robertson, PhD;** *Managing Director, H.I.G. Ventures*

**John W. Sharkey, PhD;** *Vice President, Business Development, Sciele Pharma, Inc.*

---

## **2c. BIOENERGY: A FUEL FOR SUCCESS**

As oil prices continue to rise and concerns of greenhouse gas emissions become more serious, Georgia pine forests are poised to provide relief for these energy and environmental concerns. Georgia is uniquely positioned to be a leader in the production of pine biomass and commercializing a cellulosic fuels industry. Speakers will discuss the latest advances in technology, status of the developing industry, and the benefits to our region.

**Jill Stuckey - Moderator;** *Director, Georgia Energy Innovation Center*

**Nathan McClure - Moderator;** *Director of Forest Energy and Development, Georgia Forestry Commission*

**Ron Barmore;** *Director of Project Development, Range Fuels, Inc.*

**James Fang, PhD;** *Director of Engineering, Sriya Innovations, Inc.*

**Joy Doran Peterson, PhD;** *Chair, Biofuels, Biopower, and Biomaterials Initiative, The University of Georgia*

---

## **2d. WHY GEORGIA?: THE ASCENT AND MATURATION OF GEORGIA'S TALENT POOL AND BIOTECH LABOR MARKET PRESENTED BY THE GABIO EMERGING LEADERS NETWORK**

The first question a biotech business asks before locating in a certain region is often: "Is there a large, educated, and specialized workforce in place to support our firm?" Likewise, the first question a young biotech professional asks when choosing a market is: "Is there sufficient opportunity for advancement towards a meaningful career?" For the first time, the answer to both of those questions in Georgia is an unequivocal "Yes!" In this session, leading economic experts will discuss Georgia's human resources economics, and some of the region's leading companies will discuss the arrival of Georgia as a mature hotbed of talent competitive with any other U.S. market.

**Blaine W. Lindsey - Moderator;** *Attorney at Law, Representative, GaBio Emerging Leaders Network*

**Mark Banks;** *Vice President of Human Resources, Sciele Pharma, Inc.*

**Amanda DePalma;** *Director, Global Strategic Marketing, Kimberly-Clark Health Care*

**Jeffrey M. Humphreys;** *Director, Selig Center, Terry College of Business, The University of Georgia*